X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PFIZER ALEMBIC PHARMA/
PFIZER
 
P/E (TTM) x 26.6 24.2 110.0% View Chart
P/BV x 6.1 3.8 157.9% View Chart
Dividend Yield % 0.8 0.8 92.1%  

Financials

 ALEMBIC PHARMA   PFIZER
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
PFIZER
Mar-16
ALEMBIC PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs7922,724 29.1%   
Low Rs4431,611 27.5%   
Sales per share (Unadj.) Rs167.0440.9 37.9%  
Earnings per share (Unadj.) Rs38.248.7 78.4%  
Cash flow per share (Unadj.) Rs42.075.8 55.4%  
Dividends per share (Unadj.) Rs4.0015.00 26.7%  
Dividend yield (eoy) %0.60.7 93.6%  
Book value per share (Unadj.) Rs84.9462.9 18.3%  
Shares outstanding (eoy) m188.5245.75 412.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.9 75.2%   
Avg P/E ratio x16.244.5 36.3%  
P/CF ratio (eoy) x14.728.6 51.4%  
Price / Book Value ratio x7.34.7 155.3%  
Dividend payout %10.530.8 34.0%   
Avg Mkt Cap Rs m116,38399,163 117.4%   
No. of employees `000NA2.9 0.0%   
Total wages/salary Rs m4,2142,758 152.8%   
Avg. sales/employee Rs ThNM6,981.7-  
Avg. wages/employee Rs ThNM954.5-  
Avg. net profit/employee Rs ThNM771.1-  
INCOME DATA
Net Sales Rs m31,48720,170 156.1%  
Other income Rs m55857 6.4%   
Total revenues Rs m31,54221,028 150.0%   
Gross profit Rs m10,0604,310 233.4%  
Depreciation Rs m7221,239 58.3%   
Interest Rs m375 707.7%   
Profit before tax Rs m9,3563,923 238.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m2,1601,794 120.4%   
Profit after tax Rs m7,1942,228 322.9%  
Gross profit margin %31.921.4 149.5%  
Effective tax rate %23.145.7 50.5%   
Net profit margin %22.811.0 206.9%  
BALANCE SHEET DATA
Current assets Rs m15,06616,299 92.4%   
Current liabilities Rs m7,6747,594 101.1%   
Net working cap to sales %23.543.2 54.4%  
Current ratio x2.02.1 91.5%  
Inventory Days Days6765 102.6%  
Debtors Days Days4126 157.8%  
Net fixed assets Rs m8,2378,622 95.5%   
Share capital Rs m377458 82.4%   
"Free" reserves Rs m15,41620,722 74.4%   
Net worth Rs m16,00521,180 75.6%   
Long term debt Rs m025 0.0%   
Total assets Rs m24,59429,137 84.4%  
Interest coverage x255.2755.5 33.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.7 184.9%   
Return on assets %29.47.7 383.7%  
Return on equity %44.910.5 427.3%  
Return on capital %58.719.0 308.9%  
Exports to sales %55.70.1 93,689.9%   
Imports to sales %10.417.5 59.6%   
Exports (fob) Rs m17,55112 146,256.7%   
Imports (cif) Rs m3,2833,526 93.1%   
Fx inflow Rs m17,81152 34,483.1%   
Fx outflow Rs m5,318140 3,799.1%   
Net fx Rs m12,493-88 -14,143.0%   
CASH FLOW
From Operations Rs m9,3043,436 270.8%  
From Investments Rs m-3,105-6,991 44.4%  
From Financial Activity Rs m-1,959-619 316.6%  
Net Cashflow Rs m4,240-4,174 -101.6%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 4.9 185.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.7 58.6%  
Shareholders   49,328 85,207 57.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  WOCKHARDT LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ALEMBIC LTD COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS